Abstract:Dietary fats are important for human health, yet it is not fully understood how different fats affect various health problems. Although polyunsaturated fatty acids (PUFAs) are generally considered as highly oxidizable, those of the n-3 series can ameliorate the risk of many age-related disorders. Coenzyme Q (CoQ) is both an essential component of the mitochondrial electron transport chain and the only lipid-soluble antioxidant that animal cells can synthesize. Previous work has documented the protective antioxidant properties of CoQ against the autoxidation products of PUFAs. Here, we have explored in vitro and in vivo models to better understand the regulation of CoQ biosynthesis by dietary fats. In mouse liver, PUFAs increased CoQ content, and PUFAs of the n-3 series increased preferentially CoQ10. This response was recapitulated in hepatic cells cultured in the presence of lipid emulsions, where we additionally demonstrated a role for n-3 PUFAs as regulators of CoQ biosynthesis via the upregulation of several COQ proteins and farnesyl pyrophosphate levels. In both models, n-3 PUFAs altered the mitochondrial network without changing the overall mitochondrial mass. Furthermore, in cellular systems, n-3 PUFAs favored the synthesis of CoQ10 over CoQ9, thus altering the ratio between CoQ isoforms through a mechanism that involved downregulation of farnesyl diphosphate synthase activity. This effect was recapitulated by both siRNA silencing and by pharmacological inhibition of farnesyl diphosphate synthase with zoledronic acid. We highlight here the ability of n-3 PUFAs to regulate CoQ biosynthesis, CoQ content, and the ratio between its isoforms, which might be relevant to better understand the health benefits associated with this type of fat. Additionally, we identify for the first time zoledronic acid as a drug that inhibits CoQ biosynthesis, which must be also considered with respect to its biological effects on patients.

Coenzyme Q at the Hinge of Health and Metabolic Diseases

Understanding Coenzyme Q

Biosynthesis, Deficiency, and Supplementation of Coenzyme Q

Metabolic Targets of Coenzyme Q10 in Mitochondria

Coenzyme Q10 Supplementation in Aging and Disease

The Emerging Role Of Coenzyme Q-10 In Aging, Neurodegeneration, Cardiovascular Disease, Cancer And Diabetes Mellitus

Coenzyme Q10 and Cardiovascular Diseases

Disorders of Human Coenzyme Q10 Metabolism: An Overview

The Roles of Coenzyme Q in Disease: Direct and Indirect Involvement in Cellular Functions

The Use of Coenzyme Q10 in Cardiovascular Diseases

Coenzyme Q10 supplementation – In ageing and disease

Coenzyme Q10 Supplementation for the Reduction of Oxidative Stress: Clinical Implications in the Treatment of Chronic Diseases

An AlphaFold Structure Analysis of COQ2 as Key a Component of the Coenzyme Q Synthesis Complex

The mitochondrial coenzyme Q junction and complex III: biochemistry and pathophysiology

Coenzyme Q10: A Ubiquitous Supplemental Enzyme Contributing to the Health

Primary Coenzyme Q10 Deficiency: An Update

Coenzyme Q biosynthetic proteins assemble in a substrate-dependent manner into domains at ER–mitochondria contacts

Coenzyme Q10 deficiency can be expected to compromise Sirt1 activity

Regulation of hepatic coenzyme Q biosynthesis by dietary omega-3 polyunsaturated fatty acids

Coenzyme Q Biosynthesis: An Update on the Origins of the Benzenoid Ring and Discovery of New Ring Precursors